Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Novel Measures for Alzheimer's Disease Prevention Trials (NoMAD)

Start: February 25, 2019
End: May 2024
Enrollment: 400

What Is This Study About?

This study is recruiting volunteers with no cognitive impairment to help test new assessments of cognition and everyday function. The assessments are being developed for use in Alzheimer's prevention trials. Participants will be randomly assigned to receive three assessments, either novel or established, over a one-year period.

Do I Qualify To Participate in This Study?

Minimum Age: 60 Years

Maximum Age: 85 Years

Must have:

  • English speaking
  • Mini-Mental State Examination score of 24 or greater
  • Logical Memory II score of 9 or greater for individuals with 16 or more years of education, 5 or more for individuals with 8 to 15 years of education, and 3 or greater for individuals with 0 to 7 years of education
  • Subjective memory complaints not exclusionary
  • Family member or other individual who has regular contact with the participant and can provide information during the study

Must NOT have:

  • Diagnosis of stroke or excessive risk of cardiovascular disease
  • Neurologic disease, including movement disorders, multiple sclerosis, epilepsy, and traumatic brain injury with loss of consciousness for 15 minutes or more
  • Untreated diabetes
  • Psychiatric diagnosis of schizophrenia or bipolar disorder, or current major depression as determined by a Geriatric Depression Scale score of greater than 5
  • Current alcohol or substance use disorder
  • Active treatment of cancer
  • Women who are premenopausal or are pregnant
  • Prohibited medications: antidepressants with large anticholinergic properties, including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, isocarboxazide, lithium, maprotiline, mirtazapine, nortriptyline, tranylcypromine trimipramine, and phenelzine

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: New York State Psychiatric Institute

Collaborator Sponsor

  • Columbia University
  • University of Southern California
  • Feinstein Institute for Medical Research
  • University of Miami

Source: ClinicalTrials.gov ID: NCT03900273

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health